Best in Biotech 28 May 2018 Top Medical Devices Bringing Innovation to Europe in 2018 …this system was able to reduce hypoglycemic events — when blood sugar levels drop dangerously low — by 29% in adults and by 39% in adolescents. On top of that… May 28, 2018 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 May 2025 Seven lung cancer companies advancing new treatments in 2025 …are now taking place for Zepzelca, which is an alkylating drug that binds guanine residues within DNA, triggering a cascade of events that can affect the activity of DNA-binding proteins,… May 20, 2025 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Dec 2024 10 biotech companies to watch in 2025 …and also showed that it was safe, with no associated neuroimaging adverse events. Blarcamesine has also successfully completed a phase 2 proof-of-concept study in Parkinson’s disease dementia, and a phase… December 16, 2024 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 30 Aug 2022 Biotech incubators scramble to tackle lab space crunch …biotech founders is by making its lab space easily modifiable for their individual needs. Other provisions include shared equipment rooms, meeting rooms and networking events. In 2022, the facility delivered… August 30, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials …neurofibrillary tangles, made up of tau aggregates, in the brain — a feature that it shares with Alzheimer’s disease. Inhibition of the O-GlcNAcase enzyme prevents certain sugar residues from being… April 6, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2022 Finnish and US companies form exclusive agreement for development of sustained release drug …GA, met its pre-specified primary efficacy endpoint with statistical significance. The most frequently reported ocular adverse events in this trial were related to the injection procedure. Clinical trial The Company… July 6, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 4 Dec 2023 FDA CAR-T cell therapy warning: Are T cells malignant? …of this investigation emphasize the importance of continuous monitoring and lifelong surveillance for new malignancies following CAR-T cell therapy. Proactive reporting of suspected adverse events, including T cell malignancies, to… December 4, 2023 - 4 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug …treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Once a day treatment for 10 consecutive days with intranasal foralumab was… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2023 The ongoing search for an HIV cure: can CRISPR crack the code? …feasibility of genetically-edited stem cell transplantation for AIDS treatment,” he said. In fact, he referred to it as a success because the scientists didn’t detect any gene editing-related adverse events,… October 30, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 8 Dec 2023 Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer …change in best corrected visual acuity compared to aflibercept control, as well as a favorable safety profile with no serious adverse events taking place. The key secondary endpoints were also… December 8, 2023 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? …events caused by the drug, as 73% of participants experienced nausea, 47% reported vomiting, and 25% suffered diarrhea. Furthermore, before that, Pfizer also had to discontinue the development of its… July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2022 Opportunities and challenges for cell and gene therapy investments …events. Investors can also take advantage of the situation to separate the strongest companies from the weakest. “The reality is that most products don’t succeed commercially,” said Schimmer. “If we… October 20, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email